

API PRODUCT LIST 2023

序号 No.	登记号 registration number	英文名称 API name	category	CAS	adaptation disease	包装规格 packing specification	更新日期 date updated	与制剂共 同审评审 批结果 status on CDE
1	Y2021000121 4	Dutasteride	urologic	164656-23-9	It can be used to treat moderate to severe symptoms of benign prostatic hyperplasia (BPH). Used in patients with moderate to severe benign prostatic hyperplasia to reduce the risk of acute urinary retention (AUR) and surgery.	50g/bag, 100g/ bag, 200g/bag	28/03/2023	A
2	Y2021000097 9	dapagliflozin	diabetic	461432-26-8	It is indicated as an adjunctive to diet and exercise to improve blood sugar control in adults with type 2 diabetes.	3.5Kg/bag	07/06/2023	A
3	Y2021000043 9	Eldecalcitol	osteoporosis	104121-92-8	Aldesalcitol can simultaneously improve bone metabolism and promote calcium absorption, improve bone density and bone strength, and thus reduce the incidence of osteoporotic fractures. Treatment of osteoporosis in postmenopausal women.	1g/bottle	27/10/2022	A
4	Y2021000021 3	Icosapent Ethyl	cardiovascular	84494-70-2	It is indicated as a dietary aid to reduce triglyceride (TG) levels in adult patients with severe ($\geq 500\text{mg/dL}$) hypertriglyceridemia. Used in patients with high cardiovascular risk to reduce the risk of cardiovascular events.	5kg/bottle, 10 kg /bottle, 20kg /bottle	07/02/2023	A
5	Y2020000097 5	Calcitriol	renal osteopathy (os teoporosis)	32222-06-3	Clinically, this drug can be used to treat hypocalcemia, hypoparathyroidism (adult), osteomalacia, rickets (infant), chronic kidney disease, renal bone disease, osteoporosis, and prevent osteoporosis caused by glucocorticoid.	0.1g/bottle, 0.5 g/bottle, 1.0g/b ottle, 5.0g/bottl e	31/10/2022	A
6	Y2019000101 3	Omega-3-acid ethyl esters	cardiovascular	\	This product is used to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia ($\geq 500\text{mg/dL}$)	5kg/bottle,10kg/ bottle,20kg/bottl e	06/12/2019	A
7	Y2019000976 6	Moxifloxacin Hydrochloride	antibiotic	186826-86-8	Moxifloxacin hydrochloride can be used to treat socially acquired pneumonia caused by Staphylococcus aureus, influenzae, pneumococcus, Moraxella mucositis, pneumococcus, acute episodes of chronic bronchitis, acute sinusitis and so on.	20kg/bag	12/06/2019	A
	186826-86-8			A				

8	Y2018000164 4	celecoxib	Anti-inflammatory , analgesia	169590-42-5	It has anti-inflammatory and analgesic effects and is clinically suitable for the treatment of acute and chronic osteoarthritis and rheumatoid arthritis.	bulk	18/01/2019	A
9	Y2017000154 8	Solifenacin succinate	urologic	242478-38-2	Treatment of urinary incontinence and/or frequent and urgent urination in patients with overactive bladder.	bulk	24/03/2023	A
10	Y2017000119 8	Paricalcitol	secondary hyperparathyroidism	131918-61-1	This product is used to treat secondary hyperparathyroidism in patients with chronic renal failure undergoing hemodialysis.	-	19/10/2022	A
11	Y2023000047 2	agomelatine	antidepressant	138112-76-2	It is suitable for the treatment of major depressive episodes in adult patients	5kg/bag, 10kg/bag	07/06/2023	I
12	Y2023000028 0	Fish oil (rich in omega-3 acids)	parenteral nutrition	\	Parenteral nutrition therapy	50kg/drum	11/04/2023	I
13	Y2022000128 1	Beraprost sodium	anticoagulant	88475-69-8	It is suitable for pulmonary hypertension, chronic arterial occlusive disease caused by intermittent claudication, pain and cold and other symptoms.	5g/bottle, 6g/bottle, 10g/bottle, 12g/bottle	12/01/2023	I
14	Y2022000079 4	linezolid	antibacterial	165800-03-3	This product is used for the treatment of the following infections caused by specific microbial sensitive strains: hospital-acquired pneumonia, community-acquired pneumonia, complex skin and skin soft tissue infections, including diabetic foot infections without osteomyelitis, uncomplicated skin and skin soft tissue infections, vancomycin-resistant enterococcus faecium infections, including concomitant bacteremia.	10kg/bag, 5kg/bag	16/09/2022	I
15	Y2022000019 3	Teprenone	stomach medicine	6809-52-5	It is a new type of protective drug, mainly used in the treatment of acute and chronic gastritis and gastric ulcer, and its effect on the treatment of active inflammation, the improvement of ulcer healing quality and the reduction of ulcer recurrence rate is particularly significant.	5kg/bottle	17/03/2022	I
16	Y2022000005 0	Morinidazole	antibacterial	92478-27-8	Is a novel 5-nitroimidazole antimicrobial agent for the study of bacterial infections, including anaerobic bacteria caused by appendicitis pelvic inflammatory disease (PID).	7kg/bag	27/01/2022	I
17	Y2021000120 7	Refined olive oil	parenteral nutrition	8001-25-0	Parenteral nutrition therapy	20kg/drum, 50kg/drum	24/07/2023	A
18	Y2021000107 5	fish oil triglycerides	parenteral nutrition	\	Parenteral nutrition to relieve cholestasis	50kg/drum	24/07/2023	A